Tuesday, May 1, 2018

MissionIRNewsBreaks – Earth Science Tech, Inc. (ETST) Aims to Complete White Paper Studies in Early 2019

Earth Science Tech (OTC: ETST), an innovative biotech company focused on the cannabidiol (“CBD”), nutraceutical and pharmaceutical fields, anticipates completion of white paper studies in early 2019, with clinical trials to follow. An article discussing the company reads: “Earth Science Tech, Inc. (OTC: ETST) has set 2019 as the crucial year when the company anticipates completion of white paper studies and the start of human clinical trials to investigate the synergies of drugs that are intended to treat opioid dependency. It intends to test the effectiveness of combination drugs that contain a mineral element and full spectrum cannabinoid industrial hemp oil (http://ibn.fm/06OYj). … The clinical trials are expected to commence in 2019 or later. The goal is to produce an over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug to battle opioid dependency.”
To view the full article, visit http://ibn.fm/kLVSX
About Earth Science Tech, Inc.
Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil. For more information, visit the company’s website at www.EarthScienceTech.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html